PrEP: Evidence-based prevention of HIV infection in at-risk individuals
The goal of this activity is to educate prescribers about the safety and efficacy of pre-exposure prophylaxis (PrEP) with tenofovir plus emtricitabine for reducing the risk of acquiring human immunodeficiency virus (HIV). Along with the latest data on HIV epidemiology, recommendations are made for implementing an ongoing prevention program, including identifying patients who can benefit from PrEP and a schedule for follow-up assessments.
View PDF documents below:
CME credit available from Harvard Medical School through March 2020. (0.75 Credits)